Fosfomycin sodium

磷霉素钠

Report date: 2023/02/27 20:00:18
NMEQIDP

Base Information

Drug NameFosfomycin sodium
Drug Alias Namephosphomycinfosfomycinumfosfomycinefosfomicinaphosphonomycin +[11] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionPeptidoglycan inhibitorsCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsPyelonephritisPrecursor Cell Lymphoblastic Leukemia-LymphomaUrinary Tract Infections +[4] 
Global Approved IndicationsUrinary Tract InfectionsBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesNabriva Therapeutics AgNipro Pharma CorpMeitheal Pharmaceuticals Inc +[4] 
Inactive CompaniesCardeas PharmaNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaUrinary Tract InfectionsBacterial Infections
Inactive IndicationsPyelonephritis

Other Information

ATC CodeJ01XX01
Related LinksWikipediaDrugBankKEGG